Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here CERVIVA > News

News

Cervical Cancer Prevention Information Session

Thu, 2018-01-25

Its European Cervical Cancer Prevention Week (28th January- 3rd February, 2018).

CERVIVA are supporting the national Pearl of Wisdom campaign to promote awareness about cervical cancer prevention.

Come and join us on Friday the 2nd February, 2018 , from 12.30-2pm in The Science Gallery, Trinity College, Dublin to learn more about cervical cancer prevention and #sharethewisdom.

Vacancy for CERVIVA Research Fellow

Mon, 2017-09-11

We are currently hiring a researcher to work on a HRB and CervicalCheck co-funded project to look at cervical screening uptake in women.

CERVIVA joins the HPV Vaccination Alliance

Thu, 2018-01-25

The HPV Vaccination Alliance is a group of organisations that have come together to sign a contract against cancer, specifically HPV-related cancers. CERVIVA are delighted to be a committed member of the Alliance.

National HPV Awareness Day on the 27th January 2017

Mon, 2016-12-12

CERVIVA is delighted to announce that it will host a National HPV Awareness Day on the 27th January 2017. The symposium is targeted at healthcare professionals interested or working in the area. It aims to review the burden of HPV associated cancers in men and women globally and recent developments in this field.

The importance of preparatory sensory information for follow-up procedures in cervical cancer screening

Mon, 2016-07-18

A new paper published by researchers from CERVIVA sheds light on women’s sensory experiences of colposcopy and related procedures. The findings of the research suggest women require more preparatory sensory information.

CERVIVA researcher wins best oral presentation award at the BSCCP 2016 meeting

Wed, 2016-06-08

Dr Prerna Tewari, CERVIVA HRB ICE Fellow, was recently awarded best oral presentation at the British Society for Colposcopy & Cervical Pathology (BSCCP(link is external)) 2016 meeting. The winning presentation was on the role of triage markers (e.g. HPV mRNA, p16/Ki67) in the management of HPV positive women presenting at colposcopy with minor cytological abnormalities.

The addition of p16/Ki-67 to HPV testing leads to more accurate stratification of minor cervical abnormalities

Mon, 2016-03-21

CERVIVA researchers have recently published significant findings on the triage of minor abnormal cervical cytology, LSIL and ASCUS. In recent years there has been widespread implementation of HPV testing as part of cervical screening and triage of minor cervical abnormalities. However, due to the nature of HPV infections, HPV DNA testing can still lead to a high number of women being referred to colposcopy. The aim of this paper was to expand the knowledge of existing HPV-based tests by investigating more specific methods that may highlight those women at true risk of high grade cervical pre-cancer.

CERVIVA study explores the effectiveness of HPV testing as a first-line cervical screening method

Wed, 2016-01-20

A new HPV primary screening pilot study was launched in September in partnership with CervicalCheck(link is external), the National Cervical Screening Programme. The study researchers are aiming to enrol 15,000 women who are attending primary healthcare/GP practices across Ireland, for their regular CervicalCheck smear test – recruitment for the study is currently underway and the study will run for up to 10 years.

Comparator Strategies in Cost-Effectiveness Analyses of HPV Testing in Cervical Screening

Wed, 2016-01-06

CERVIVA investigators have recently published a review of economic analyses of new HPV-based tests in cervical cancer screening. Screening for cervical cancer with HPV tests is generally found to be more effective than conventional screening that uses cytology tests (smear tests) alone. HPV testing can also be cost-effective as long as, like all screening interventions, it is used within appropriate age groups and is not conducted too frequently. The review showed that many economic analyses of HPV testing have not considered a sufficient number of alternative screening strategies. In particular, many analyses do not include sufficient alternative screening strategies with relatively long intervals between screens of 5 years or more. Including sufficient alternative strategies is an important aspect of a good economic analysis. The paper also highlights how it is likely that some published assessments of HPV testing produce over-optimistic cost-effectiveness estimates.

CERVIVA investigators present their research findings at HPV 2015 in Portugal

Wed, 2015-09-16

The 30th International Papillomavirus Conference (HPV 2015) takes place in Lisbon, Portugal from September 17-21. The conference focuses on HPV (human papillomavirus) which is a known cause of cervical cancer and is also implemented in other diseases (e.g. head and neck cancers). The event brings together clinicians, other health professionals and researchers to share knowledge and debate topics related to HPV.

New paper on recommendations for dealing with aspects of time in health economic evaluations

Thu, 2015-08-20

CERVIVA health economist, Dr James O'Mahony, has collaborated with researchers in Rotterdam and Sydney to publish an important paper that looks at aspects of time in health economic modelling, The article entitled Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice was recently accepted for publication in the PharmacoEconomics. 

Research on quality of life after colposcopy presented at iHEA Congress 2015

Wed, 2015-07-29

CERVIVA researcher, Mr Alan Ó Céilleachair, recently presented his work on health-related quality of life in women after colposcopy at the iHEA World Cognress 2015 in Milan. The iHEA(link is external) (International Health Economics Association) Congress is an annual event at which important topics related to the economics of health are discussed by health economists from all over the world e.g. nutrition, cancer and other related health issues.

Our new systematic review examines adverse psychological outcomes following colposcopy

Tue, 2015-06-23

Each year approximately 15,000 women who attend cervical screening, through CervicalCheck, Ireland’s national cervical cancer screening programme, receive abnormal cytology test results and require follow-up. A hospital-based colposcopy examination is the main follow-up option for women.

CERVIVA to hold research symposium on Friday 12th June 2015

Mon, 2015-05-25

CERVIVA is pleased to announce that it will hold a research symposium on the 12th June. The symposium will highlight the consortium’s research projects currently underway in the area of cervical screening and other HPV associated diseases. Professor Heather Cubie from the University of Edinburgh will be giving the keynote lecture of the day on global cervical cancer burden. Dr Grainne Flannelly, clinical director of CervicalCheck, will be giving a talk on the new cervical screening protocols and future challenges for the national screening programme.

CERVIVA researcher wins best proffered oral presentation in public health at the All-Ireland Cancer Consortium (AICC) 2015 Conference

Mon, 2015-05-18

Our CERVIVA Post-doctoral Research Fellow, Mairead O’ Connor, attended the All-Ireland Cancer Consortium (AICC) conference held in Belfast last week. The conference covered a diverse range of topics and themes in cancer research and brought together experts in the various cancer disciplines from both national and international organisations.

CERVIVA is pleased to announce the launch of it’s new website

Thu, 2015-05-07

CERVIVA, a collaborative group delivering high quality research in the area of HPV associated diseases, has just launched it’s new website- www.cerviva.ie. The new site aims to inform the general public, research institutions and health professionals about the research group- who’s involved, the objectives, and the different types of research carried out.

CERVIVA fellows attend IARC course in Lyon

Sat, 2013-06-01 

CERVIVA HRB (Health Research Board) ICE fellows Dr. Prerna Tewari and Dr. Mairead O’ Connor attended the Summer School in Cancer Epidemiology held at International Agency for Research in Cancer (IARC), Lyon. Both fellows were sponsored by the Irish Cancer Society to attend this prestigious course.

Radio interview with Dr. Martin regarding increased HPV risk of women who smoke

Wed, 2013-02-20

On the radio station Sunshine 106.8, Dr. Cara Martin, Assistant Professor at Trinity College, joined Lynsey Dolan on the line to tell us all about their research which shows that women who smoke are at a greater risk of picking up a Human Papillomavirus (HPV) infection, the main cause of cervical cancer. 

Women who smoke ‘at greater risk of HPV infection’

Tue, 2013-02-19

RESEARCH FUNDED BY the Irish Cancer Society shows that women who smoke are at greater risk of contracting a Human Papillomavirus (HPV) infection.

The infection is the main cause of cervical cancer, and HPV infects 70 – 80 per cent of women at some stage in their lifetime. According to research that was funded by a €120,000 grant from the Irish Cancer Society, women who smoke are at greater risk of contracting HPV.